ProterixBio presents COPD clinical study results at the European Respiratory Society International Congress
Billerica MA, September 12, 2017 – ProterixBio, Inc. today announced that results from a recent clinical study of subjects with chronic obstructive pulmonary disease (COPD) were presented this week at the European Respiratory Society International Congress. Algorithms based on combinations of protein biomarkers were successfully associated with measures of COPD disease activity such as shortness… Read more »
ProterixBio Joins the Industrial Advisory Boards of the COPD Foundation and the SPIROMICS Consortium
Billerica, MA, September 13, 2016 – ProterixBio, Inc. today announced that it has joined the Industrial Advisory boards of the COPD (chronic obstructive pulmonary disease) Foundation and the SPIROMICS Consortium. Joining both advisory boards reflects ProterixBio’s commitment to develop novel clinical applications including diagnostics products and disease management tools for pulmonary diseases. ProterixBio is developing… Read more »
ProterixBio and the University of Zurich Receive Michael J. Fox Foundation Grant to Develop a Novel Assay for Alpha-synuclein Aggregates
Billerica, MA – ProterixBio, Inc. today announced the receipt of a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant funds a collaboration between ProterixBio and the University of Zurich in Switzerland focused on the development of a novel bioanalytical assay workflow that aims to measure small amounts of aberrant alpha-synuclein… Read more »